Short DAPT Eligibility Calculator

Clinical calculation support · Verify results before clinical use

Clinical decision support

Assess bleeding and ischemic risk after PCI

For adults with acute coronary syndrome treated with PCI and a contemporary drug-eluting stent. Select all findings that apply, based on documented clinical assessment.

ACS · PCI
Antiplatelet review
01

First-month treatment course

Confirm timing and whether the early regimen was tolerated.

02

Bleeding risk

Use the formal ARC-HBR definition: at least 1 major criterion or at least 2 minor criteria.

03

Ischemic and anatomic risk factors

Select all that apply. These features may favor standard or longer DAPT when bleeding risk permits.

04

Concomitant anticoagulation

This changes the antithrombotic pathway and should not be interpreted as routine short-DAPT eligibility.

Clinical context

This qualitative tool supports review of DAPT duration after ACS and PCI. It does not calculate a validated numerical score and does not independently establish eligibility for single antiplatelet therapy.

How to interpret the assessment

  • For ACS patients who are not at high bleeding risk, the default strategy is DAPT for at least 12 months.
  • For selected ACS patients at high bleeding risk, transition to single antiplatelet therapy after 1 month may be reasonable after individualized assessment.
  • In patients who tolerate DAPT with ticagrelor, ticagrelor monotherapy after at least 1 month is a distinct guideline-supported bleeding-reduction strategy.
  • For patients requiring long-term oral anticoagulation, use the anticoagulation-specific pathway; aspirin discontinuation 1–4 weeks after PCI with an oral anticoagulant plus a P2Y12 inhibitor is recommended by the 2025 US guideline.
  • Complex PCI, recurrent ischemia, stent thrombosis, ventricular dysfunction, planned procedures, and patient-specific factors require clinician review rather than automatic rule-based decisions.

Important limitation

The ischemic features in this tool are qualitative prompts, not a validated score or a complete list of contraindications to abbreviated DAPT. The tool does not replace ARC-HBR assessment, formal risk tools where appropriate, angiographic/procedural review, or shared decision-making.

References

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.

J Am Coll Cardiol. 2025. doi:10.1016/j.jacc.2024.11.009

Valgimigli M, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk (MASTER DAPT).

N Engl J Med. 2021;385:1643–1655. doi:10.1056/NEJMoa2108749

Urban P, et al. Defining High Bleeding Risk in Patients Undergoing PCI: ARC-HBR Consensus Document.

Circulation. 2019;140:240–261. doi:10.1161/CIRCULATIONAHA.119.040167

Medical disclaimer: This tool is intended for healthcare professionals as clinical decision support. It is not a substitute for current guidelines, local protocols, the treating clinician’s judgment, or individualized assessment of bleeding and ischemic risk. Do not stop or change antiplatelet or anticoagulant medication solely on the basis of this output.